卵巢癌患者临终照护连续性与激进临终治疗的关系
该回顾性索赔分析纳入6680例66岁以上卵巢癌Medicare受益者,计算Bice-Boxerman照护连续性指数(COC)并分高、中、低三分位,比较多重激进临终治疗指标。结果显示49.8%的患者在生命最后一个月接受激进治疗;
要点
- 高照护连续性(COC)与卵巢癌患者临终前两周化疗几率升高66%相关。
- 高COC与未入临终关怀几率升高16%相关,但与晚期入 hospice 无关。
- COC与急诊、ICU、住院或侵入性操作等激进临终治疗无显著关联。
核心结论
- 卵巢癌患者临终照护连续性复杂,高COC与部分激进临终治疗(化疗、未入临终关怀)几率升高相关。
研究设计与样本
- 回顾性索赔分析,纳入6680例66岁以上卵巢癌Medicare受益者,诊断后存活至少1年、至少4次门诊评估管理访视,死于2000至2016年。
主要发现
- 49.8%的女性在生命最后一个月接受激进治疗。
- COC与晚期入临终关怀、住院利用或激进操作无显著关联。
关键数值与推荐
- 使用Bice-Boxerman照护连续性指数(COC),分为高、中、低三分位。
- 激进临终治疗指标包括:晚期或无临终关怀使用、>1次急诊就诊、ICU入住、>1次住院、终末住院、化疗、侵入性和/或延长生命操作。
临床怎么用
- 对卵巢癌临终患者,高照护连续性可能提示需关注化疗过度使用及临终关怀转介不足。
局限性
- 回顾性索赔分析,仅纳入66岁以上Medicare受益者,可能存在编码偏倚和未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between post-diagnosis continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. METHODS: This retrospective claims analysis included 6680 Medicare beneficiaries over age 66 with ovarian cancer who survived at least one year after diagnosis, had at least 4 outpatient evaluation and management visits and died between 2000 and 2016. We calculated the Bice-Boxerman Continuity of Care Index (COC) for each woman, and split COC into tertiles (high, medium, low). We compared late or no hospice use, >1 emergency department (ED) visit, intensive care unit (ICU) admission, >1 hospitalization, terminal hospitalization, chemotherapy, and invasive and/or life extending procedures among women with high or medium vs. low COC using multivariable adjusted logistic regression. RESULTS: In this sample, 49.8% of women received aggressive care in the last month of life. Compared to women with low COC, women with high COC had 66% higher odds of chemotherapy (adjusted OR 1.66 CI 1.23-2.24) in the last two weeks of life. Women with high COC also had 16% greater odds of not enrolling in hospice compared to women with low COC (adjusted OR 1.16 CI 1.01-1.33). COC was not associated with late enrollment in hospice, hospital utilization, or aggressive procedures. CONCLUSIONS: COC at the end of life is complicated and may pose unique challenges in providing quality end of life care. Future work exploring the specific facets of continuity associated with quality end of life care is needed.
引用
- Mullins MA, Ruterbusch JJ, Clarke P, et al. Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. Gynecol Oncol. 2021. PMID: 33931242. doi:10.1016/j.ygyno.2021.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。